New Phase II Clinical Trial on AHCC® and HPV
People with HPV that is high-risk are worried about cancer although have no idea how to avoid it. The only approaches to maintaining a strong immune system are having a good diet, obtaining enough sleep, and staying away from stressful circumstances. Patients who have overcome HPV-associated cancer and are now a part of support groups for those affected by the condition voice significant anxiety around the possibility their HPV may become active again and cause cancer.
Those who have high-risk HPV should keep a close eye on any study that looks at a dietary supplement that increases the immune system's ability to clear the body of chronic HPV illnesses. In a recent phase II trial, researchers found that AHCC® had a success rate of 58% in eliminating persistent HPV illnesses. This finding offers those who have high-risk HPV a glimmer of hope.
Persistent HPV illnesses are those that have been active for more than 2 years. The longer these diseases stay active, the greater the danger that abnormal cancer cells may begin to grow. There are a lot of individuals who, if they have a strong immune system, may recover from HPV illnesses in less than two years or even sooner. However, this is not the case for everyone. A person's immune system may be affected in various ways, including by nutritional inadequacies, lack of sleep, stress, and the natural aging process.
Roughly ten percent of those who have been infected with HPV go on to have chronic conditions that persist longer than two years. In order to effectively combat cancer, it is essential to identify instances of recurrent and high-risk HPV illnesses. At this time, there is no medication available for chronic HPV conditions that are administered systemically.
PAP smears are one method for detecting cancer at an early stage so that preventive measures may be taken. The following therapies are then accessible to choose from: cryotherapy, surgical excision, excision - loop electrosurgical, or conization (cold knife). These treatments have an 80% success rate, it is nevertheless rather typical for patients to have recurrence of their lesions. There is currently no well-established medical procedure for detecting and treating infections caused by HPV in other parts of the body, including the anus. According to the findings of the Anchor Study, reducing the risk of getting anal cancer by screening for HPV and treating precancerous cells may be accomplished.
This screening method, which is still relatively fresh, is only provided at a limited number of locations around the country. In light of this, it would be preferable to put a halt to these cell changes before they ever begin. This phase II research raises the prospect of preventing recurring HPV illnesses before they proceed to cancer by using AHCC® supplements as a treatment method.
It has been shown that the nutritional supplement known as AHCC®, which is an extract of the cultured mycelia of the lentinula edodes fungus, has anti-inflammatory and immunomodulatory activities. Numerous studies conducted on both animals and humans have uncovered a wide range of therapeutic benefits, including improved antioxidant activity, anticancer activity, and immune system modulation that helps protect against bacterial and viral infections. According to the results of this current clinical study, AHCC® may also assist in the capacity of the immune system to eliminate chronic HPV illnesses. This research is still underway.
According to the findings of two exploratory research, AHCC® showed early potential. Within three to six months of taking AHCC® on an empty stomach three times per day for women with persistent HPV illnesses, fifty percent of the participants who stayed in the experiment had their infection eliminated. This occurred in four out of the eight women who took part in the research.
In the second pilot study, women were given 1 gram of AHCC® on an empty stomach once a day for seven months. The response rate was comparable: four out of nine individuals (44 percent) confirmed that they had been cured of high-risk HPV persistent illnesses. These pilot trials paved the way for the beginning of phase II research on AHCC® to treat disorders that are persistently caused by HPV.
The New Study – Phase II
Judith Smith, who is a member of the medical advisory board, took on the role of lead investigator for this phase II randomized, placebo-controlled, double-blind trial. The Institutional Review Board of the University of Texas Health Sciences Center granted its permission for this research project. The use of AHCC® supplementation was done so that, over the course of a period of six months, the immune system of the host may be assisted in eliminating high-risk HPV illnesses.
Over the course of one year, examinations were carried out on over fifty older women who had been HPV-positive for at least two years prior to the start of the study. The AHCC® 3g orally unit dosage was administered to one group every day on an empty stomach for the first six months of the experiment, while the other group was given a placebo for the remaining time period of the study.
The group that received a placebo got nothing. Every patient had a blood sample drawn every three months for the purpose of testing for the presence of HPV-RNA and HPV-DNA as well as a variety of immunological markers, including interferon-beta (IFN), interferon-gamma (IFN), IgG1 T cells, and levels of natural killer cells. These tests were performed in order to determine whether or not the patients had been exposed to the HPV virus.
Fourteen of the twenty-two patients tested negative for HPV-DNA and HPV-RNA after six months of supplementation with AHCC®, and nine of the fourteen patients (64.3 percent) showed a sustained response by continuing to test negative for HPV-DNA and HPV-RNA after the supplementation had been discontinued for a year. After a year of follow-up testing, there were no detectable cases of HPV in any of the 19 individuals who had participated in the placebo arm of the research. After six months of AHCC® supplementation, a total of twelve more patients finished the unblinded inquiry, and the results of their tests revealed that fifty percent of them were negative for HPV DNA/HPV-RNA.
In all, there were around 34 patients who used AHCC supplements, and they had a success rate of 58.8 percent in getting rid of HPV illnesses.
When administered once daily without eating, a dosage of 3 grams of AHCC® was shown to be safe and effective in improving the ability of the host immune system to eliminate illnesses caused by HPV that are resistant to treatment.
It was shown that reducing IFN to below 20 pg/mL was related to an increase in the number of T cells and IFN and long-term eradication of HPV illnesses in women who got AHCC® supplementation. This was revealed in research conducted on women. Monitoring persons who are infected with HPV requires more investigation. Suppose we want to maximize the AHCC® supplement's long-term benefits. In that case, we need to do more research to identify how long AHCC® supplementation should be continued after an initial negative test result.
Uniqueness of AHCC
As a direct consequence of this, it is very necessary to differentiate AHCC® from several other so called medicinal mushrooms. There is currently no other anti-HPV medicine that has shown clinical effectiveness equivalent to AHCC®. There is no other medicinal mushroom that can improve this particular ingredient’s ability to enhance the body's immune system.
Several years ago, researchers in Japan made the ground-breaking discovery that cell culture is one of the most effective methods for boosting the functionality of natural killer cells. A one-of-a-kind enzymatic process was used to reduce the molecular weight of this medication to improve its ability to be absorbed by the body and its efficacy as a therapeutic agent. The authenticity of each batch of AHCC® is determined by analyzing the DNA patterns it contains using testing. AHCC® stands apart from other medicinal mushrooms on the market because of these improvements.
A wide variety of supplement companies provide make statements about being AHCC® but avoid purchasing products that make claims without having the AHCC® trademark on their label. There is only one manufacturer of AHCC® and this is a patent protected ingredient. Through the use of scientific study, it has been shown that authentic AHCC® may clear high risk HPV.
AHCC® is a registered trademark of the Amino Up Company, Ltd., JAPAN.